The latest big-ticket acquisition was announced just a month after the French drugmaker disclosed another billion-dollar deal. Shares of Sanofi fell, however, following the news, while Kadmon’s stock climbed to a five-year high.
ADSS Review
Thursday, 09 Sep, 2021 / 7:53
